Turning immune checkpoint inhibitors into synthetic switches for engineered T cells

Adoptive T cell therapy and immune checkpoint blockade have independently transformed cancer immunotherapy, yet durable responses in solid tumors remain limited by antigen heterogeneity, immunosuppressive tumor microenvironments, and inadequate control over engineered immune cell activity.1,2 Numerous strategies have sought to combine these therapeutic modalities, most commonly by using checkpoint inhibitors to relieve T cell dysfunction or by genetically disrupting inhibitory pathways3 (Figure 1).

Published in Molecular Therapy Oncology. The abstract is shown as published and remains the work of its authors; read the full article at the source.

doi.org/10.1016/j.omton.2026.201346